A similar trend has occurred ...

A similar trend occurred in the dynamics of the questionnaire autonomic changes with a significant decline in its already to 7 day and then decreasing at day 28 (respectively, 44.1, 39.1, 29.3). It should be noted that despite the distinct positive dynamics of these symptoms, even to the end of treatment, they not only reached the threshold, but also preserves its twofold excess (Fig. 3). Fast enough and statistically significant already on day 7 of treatment were reduced rates of sleep disorders, reaching borderline values ??for this disorder by the end of therapy (respectively 16,9 ± 3,3; 18,4 ± 2,8; 20,8 ± 3, 1). Significantly decreased values ??of depressive symptoms (by questionnaire Beck), reaching statistical significance in the differences at day 28 of treatment (respectively 13,6 ± 5,2; 12,7 ± 4,6; 8,3 ± 3,6). At the same time in all cases except one, the final figure is not indicative of the depression. Positive dynamics in klinicheskomsostoyanii patients treated Enerionom, marked and evaluated using Spielberger anxiety test (Fig. 4). Statistically significant decline in the Spielberger test to assess the state "in the moment" (pp 1-20) was detected as early as 7 day administration of the drug and it becomes even more pronounced at day 28 of therapy. Some difference is dynamics in the Spielberger test to assess the "normal state of health" (pp 21-40), where quantitative index also decreased, but the differences reached statistical significance only at the end of the treatment course. In accordance with the features of the clinical material, which included patients late age (and among them was dominated by patients with psevdonevrastenicheskim option psychoorganic syndrome with the manifestations of cognitive dysfunction), it seemed important to analyze changes in the cognitive area during treatment Enerionom. To this end, the patients were examined twice using mini-mental test (MMSE) and compared the performance of background investigation and at the end of therapy Enerionom (Fig. 5). Found a statistically significant increase srednegruppovogo rate mini-test (respectively, 27.9 ± 1,1; 28,7 ± 1,1). Thus, we demonstrated an additional therapeutic effect of the drug Enerion against cognitive impairment, essential for its use in patients with middle and old age. Table 2 summarizes performance indicators of various parameters of the patients treated Enerionom. Patients who completed the full course of treatment Enerionom, no change in the somatic condition. No differences in blood pressure and pulse rate before and after treatment (Table 2). Srednegruppovoe systolic blood pressure before treatment was 148,5 ± 19,6, after treatment - 148,9 ± 18,2 mmHg, diastolic BP, respectively 84,9 ± 8,5 and 86,7 ± 9,7 mm Hg. Art. The pulse rate also remained unchanged in patients receiving Eneriona (respectively 74,6 ± 9,5 and 74,2 ± 8,6).